Erlotinib-¹³C₆  (Synonyms: CP-358774-¹³C₆; NSC 718781-¹³C₆; OSI-774-¹³C₆)

Erlotinib-¹³C₆ is a ¹³C-labeled Erlotinib. Erlotinib is a directly acting EGFR tyrosine kinase inhibitor, with an IC50 of 2 nM for human EGFR[1].

Erlotinib reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM. Erlotinib is used for the treatment of non-small cell lung cancer^[1].
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

399.39

C₁₆¹³C₆H₂₃N₃O₄

1211107-68-4

183321-74-6

COCCOC(C(OCCOC)=C1)=CC2=C1C(N[13C]3=[13CH][13C](C#C)=[13CH][13CH]=[13CH]3)=NC=N2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Moyer JD, et al. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res. 1997, 57(21), 4838-4848.  [Content Brief]

  [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief]